Epigenetic changes in the myelodysplastic syndrome.

Epigenetic changes in the myelodysplastic syndrome.
复制标题

DOI:
10.1016/j.hoc.2010.02.007
复制
发表时间:
2010-04
期刊:
Hematology/oncology clinics of North America
影响因子:
--
通讯作者:
Issa JP
Issa JP
中科院分区:
其他
文献类型:
--
作者:
Issa JP

文献摘要

参考文献

被引文献

相似文献

表观遗传机制,如DNA甲基化和组蛋白修饰驱动基因表达的稳定,克隆传播的变化,因此可以作为肿瘤形成的途径功能障碍的分子介质。MDS的特征在于频繁的表观遗传异常,包括控制增殖、粘附和该白血病的其他特征的基因的超甲基化。异常的DNA高甲基化与MDS的不良预后相关,其可以通过更快地进展为AML来解释。反过来,用修饰表观遗传途径的药物(DNA甲基化和组蛋白脱乙酰化抑制剂)治疗可诱导MDS的持久缓解并延长其生命,为这种致命疾病的未来管理提供了一些希望和方向。
Epigenetic mechanisms such as DNA methylation and histone modifications drive stable, clonally propagated changes in genes expression and can therefore serve as molecular mediators of pathway dysfunction in neoplasia. MDS is characterized by frequent epigenetic abnormalities, including the hypermethylation of genes that control proliferation, adhesion, and other characteristic features of this leukemia. Aberrant DNA hypermethylation is associated with a poor prognosis in MDS that can be accounted for by more rapid progression to AML. In turn, treatment with drugs that modify epigenetic pathways (DNA methylation and histone deacetylation inhibitors) induce durable remissions and prolong life in MDS, offering some hope and direction in the future management of this deadly disease.
DOI: 10.1016/s0037-1963(03)00196-3
发表时间: 2003-10-01
影响因子: 3.6
作者:
Armstrong, SA;Golub, TR;Korsmeyer, SJ
通讯作者: Korsmeyer, SJ
DOI: 10.1111/j.1600-0609.2005.00559.x
发表时间: 2006-01-01
影响因子: 3.1
作者:
Aggerholm, A;Holm, MS;Hokland, P
通讯作者: Hokland, P
DOI: 10.1038/5047
发表时间: 1999-01-01
期刊: NATURE GENETICS
影响因子: 30.8
作者:
Cameron, EE;Bachman, KE;Baylin, SB
通讯作者: Baylin, SB
DOI: 10.1182/blood.v89.6.2079
发表时间: 1997-03-15
期刊: BLOOD
影响因子: 20.3
作者:
Greenberg, P;Cox, C;Bennett, J
通讯作者: Bennett, J
DOI: 10.1038/71750
发表时间: 2000-01-01
期刊: NATURE GENETICS
影响因子: 30.8
作者:
Fuks, F;Burgers, WA;Kouzarides, T
通讯作者: Kouzarides, T